Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 231

1.

Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohort.

Hebeisen M, Micheroli R, Scherer A, Baraliakos X, de Hooge M, van der Heijde D, Landewé R, Bürki K, Nissen MJ, Möller B, Zufferey P, Exer P, Ciurea A.

PLoS One. 2020 Mar 20;15(3):e0230268. doi: 10.1371/journal.pone.0230268. eCollection 2020.

2.

Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review.

Baraliakos X, Gensler LS, D'Angelo S, Iannone F, Favalli EG, de Peyrecave N, Auteri SE, Caporali R.

Ther Adv Musculoskelet Dis. 2020 Mar 4;12:1759720X20906040. doi: 10.1177/1759720X20906040. eCollection 2020. Review.

3.
4.

Imaging of diffuse idiopathic skeletal hyperostosis (DISH).

Mader R, Baraliakos X, Eshed I, Novofastovski I, Bieber A, Jorrit-Jan Verlaan JJ, Kiefer D, Pappone N, Atzeni F.

RMD Open. 2020 Feb;6(1). pii: e001151. doi: 10.1136/rmdopen-2019-001151. Erratum in: RMD Open. 2020 Mar;6(1):.

5.

The phenotype of axial spondyloarthritis: is it dependent on HLA-B27 status?

Coates LC, Baraliakos X, Blanco FJ, Blanco-Morales E, Braun J, Chandran V, Luiz Fernandez-Sueiro J, FitzGerald O, Gallagher P, Gladman DD, Gubar E, Korotaeva T, Loginova E, Lubrano E, Mulero J, Pinto J, Queiro R, Sanz J, Szentpetery A, Helliwell PS.

Arthritis Care Res (Hoboken). 2020 Feb 26. doi: 10.1002/acr.24174. [Epub ahead of print]

PMID:
32100954
6.

Diagnostic capability of contrast-enhanced pelvic girdle magnetic resonance imaging in polymyalgia rheumatica.

Fruth M, Seggewiss A, Kozik J, Martin-Seidel P, Baraliakos X, Braun J.

Rheumatology (Oxford). 2020 Feb 20. pii: keaa014. doi: 10.1093/rheumatology/keaa014. [Epub ahead of print]

PMID:
32077962
7.

[Establishment of classification criteria for axial spondyloarthitis-how far is good for making diagnoses?]

Braun J, Kiltz U, Baraliakos X.

Z Rheumatol. 2020 Mar;79(2):132-134. doi: 10.1007/s00393-020-00752-z. German. No abstract available.

PMID:
32040753
8.

Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS).

Baraliakos X, Østergaard M, Gensler LS, Poddubnyy D, Lee EY, Kiltz U, Martin R, Sawata H, Readie A, Porter B; SURPASS Study Group.

Clin Drug Investig. 2020 Mar;40(3):269-278. doi: 10.1007/s40261-020-00886-7.

PMID:
31983056
9.

Response to: 'Frequency of MRI changes suggestive of axial spondyloarthritis in the axial in a large population-based cohort of individuals aged <45 years' by Parperis.

Baraliakos X, Richter A, Schmidt CO, Braun J.

Ann Rheum Dis. 2020 Jan 3. pii: annrheumdis-2019-216798. doi: 10.1136/annrheumdis-2019-216798. [Epub ahead of print] No abstract available.

PMID:
31900303
10.

[Clinical significance of determination of DFS70 antibodies to rule out connective tissue diseases].

Kiefer D, von Brunn M, Baraliakos X, Andreica I, Braun J.

Z Rheumatol. 2019 Dec 30. doi: 10.1007/s00393-019-00741-x. [Epub ahead of print] German.

PMID:
31889213
11.

Reply to: Bone marrow oedema on sacroiliac/spine MRI: is it really a sign of objective inflammation warranting treatment?

Baraliakos X, Anderson JK.

Clin Exp Rheumatol. 2019 Nov-Dec;37 Suppl 122(6):11-12. Epub 2019 Dec 12. No abstract available.

12.

[Imaging of psoriatic arthritis and aspects of radiographic progression].

Baraliakos X, Kleyer A, Simon D, Köhm M, Ohrndorf S, Sewerin P.

Z Rheumatol. 2020 Feb;79(1):40-52. doi: 10.1007/s00393-019-00735-9. Review. German.

PMID:
31822993
13.

[Imaging in patients with axial spondylarthritis with focus on new bone formation].

Baraliakos X, Braun J.

Z Rheumatol. 2020 Feb;79(1):33-39. doi: 10.1007/s00393-019-00732-y. Review. German.

PMID:
31822992
14.

[Biosimilars and the nocebo effect].

Braun J, Tsiami S, Buehring B, Kiefer D, Andreica I, Baraliakos X, Kiltz U.

Z Rheumatol. 2019 Dec 4. doi: 10.1007/s00393-019-00729-7. [Epub ahead of print] German.

PMID:
31802197
15.

Do NSAIDs affect radiographic progression in axial SpA?

Braun J, Baraliakos X.

Nat Rev Rheumatol. 2020 Jan;16(1):9-10. doi: 10.1038/s41584-019-0341-4. No abstract available.

PMID:
31758152
16.

Frequency of MRI changes suggestive of axial spondyloarthritis in the axial skeleton in a large population-based cohort of individuals aged <45 years.

Baraliakos X, Richter A, Feldmann D, Ott A, Buelow R, Schmidt CO, Braun J.

Ann Rheum Dis. 2020 Feb;79(2):186-192. doi: 10.1136/annrheumdis-2019-215553. Epub 2019 Nov 19.

PMID:
31744822
17.

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).

Dougados M, Wei JC, Landewé R, Sieper J, Baraliakos X, Van den Bosch F, Maksymowych WP, Ermann J, Walsh JA, Tomita T, Deodhar A, van der Heijde D, Li X, Zhao F, Bertram CC, Gallo G, Carlier H, Gensler LS; COAST-V and COAST-W Study Groups.

Ann Rheum Dis. 2020 Feb;79(2):176-185. doi: 10.1136/annrheumdis-2019-216118. Epub 2019 Nov 4.

18.

The impact of sex and disease classification on patient-reported outcome measures in axial spondyloarthritis: a descriptive prospective cross-sectional study.

Andreasen RA, Kristensen LE, Egstrup K, Baraliakos X, Strand V, Horn HC, Hansen IMJ, Christensen R, Ellingsen T.

Arthritis Res Ther. 2019 Oct 29;21(1):221. doi: 10.1186/s13075-019-2012-x.

19.

Does psoriatic axial spondyloarthritis phenotype correlate with imaging morphotype?

Gensler LS, Szumski A, Jones HE, Baraliakos X.

Clin Exp Rheumatol. 2020 Mar-Apr;38(2):329-332. Epub 2019 Oct 1.

PMID:
31577217
20.

Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study.

Baraliakos X, Braun J, Deodhar A, Poddubnyy D, Kivitz A, Tahir H, Van den Bosch F, Delicha EM, Talloczy Z, Fierlinger A.

RMD Open. 2019 Sep 3;5(2):e001005. doi: 10.1136/rmdopen-2019-001005. eCollection 2019.

21.

Treat to Target in Axial Spondyloarthritis.

Nikiphorou E, Baraliakos X.

Rheum Dis Clin North Am. 2019 Nov;45(4):519-535. doi: 10.1016/j.rdc.2019.07.003. Epub 2019 Aug 17. Review.

PMID:
31564294
22.

[Erratum to: Epionics SPINE-use of an objective method to examine spinalmobility in patients with axial spondyloarthritis].

Kiefer D, Baraliakos X, Bühring B, Kiltz U, Braun J.

Z Rheumatol. 2019 Oct;78(8):773-774. doi: 10.1007/s00393-019-00715-z. German. No abstract available.

PMID:
31541287
23.

[Early recognition and screening consultation: a necessary way to improve early detection and treatment in rheumatology? : Overview of the early recognition and screening consultation models for rheumatic and musculoskeletal diseases in Germany].

Benesova K, Lorenz HM, Lion V, Voigt A, Krause A, Sander O, Schneider M, Feuchtenberger M, Nigg A, Leipe J, Briem S, Tiessen E, Haas F, Rihl M, Meyer-Olson D, Baraliakos X, Braun J, Schwarting A, Dreher M, Witte T, Assmann G, Hoeper K, Schmidt RE, Bartz-Bazzanella P, Gaubitz M, Specker C.

Z Rheumatol. 2019 Oct;78(8):722-742. doi: 10.1007/s00393-019-0683-y. Review. German.

PMID:
31468170
24.

[Epionics SPINE-use of an objective method to examine spinal mobility in patients with axial spondyloarthritis].

Kiefer D, Baraliakos X, Bühring B, Kiltz U, Braun J.

Z Rheumatol. 2020 Mar;79(2):143-152. doi: 10.1007/s00393-019-00692-3. German. Erratum in: Z Rheumatol. 2019 Oct;78(8):773-774.

PMID:
31468167
25.

Nonsteroidal anti-inflammatory drugs and cardiovascular risk - a matter of indication.

Braun J, Baraliakos X, Westhoff T.

Semin Arthritis Rheum. 2020 Apr;50(2):285-288. doi: 10.1016/j.semarthrit.2019.07.012. Epub 2019 Aug 1. Review.

PMID:
31439354
26.

MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group.

Maksymowych WP, Lambert RG, Østergaard M, Pedersen SJ, Machado PM, Weber U, Bennett AN, Braun J, Burgos-Vargas R, de Hooge M, Deodhar AA, Eshed I, Jurik AG, Hermann KA, Landewé RB, Marzo-Ortega H, Navarro-Compán V, Poddubnyy D, Reijnierse M, Rudwaleit M, Sieper J, Van den Bosch FE, van der Heijde D, van der Horst-Bruinsma IE, Wichuk S, Baraliakos X.

Ann Rheum Dis. 2019 Nov;78(11):1550-1558. doi: 10.1136/annrheumdis-2019-215589. Epub 2019 Aug 17.

PMID:
31422357
27.

Current status of use of big data and artificial intelligence in RMDs: a systematic literature review informing EULAR recommendations.

Kedra J, Radstake T, Pandit A, Baraliakos X, Berenbaum F, Finckh A, Fautrel B, Stamm TA, Gomez-Cabrero D, Pristipino C, Choquet R, Servy H, Stones S, Burmester G, Gossec L.

RMD Open. 2019 Jul 18;5(2):e001004. doi: 10.1136/rmdopen-2019-001004. eCollection 2019.

28.

Imaging in the preclinical phases of rheumatoid arthritis.

Zabotti A, Finzel S, Baraliakos X, Aouad K, Ziade N, Iagnocco A.

Clin Exp Rheumatol. 2019 Jul 25. [Epub ahead of print] Review.

PMID:
31376263
29.

Observation by Magnetic Resonance Imaging of Sacroiliac Joint Ankylosis in Young Spondyloarthritis Patients Receiving Biologic Therapy: Comment on the Article by Bray et al.

Braun J, Kiltz U, Baraliakos X.

Arthritis Rheumatol. 2019 Dec;71(12):2128-2129. doi: 10.1002/art.41050. Epub 2019 Oct 21. No abstract available.

PMID:
31328408
30.

Implementation and role of modern musculoskeletal imaging in rheumatological practice in member countries of EULAR.

Mandl P, Ciechomska A, Terslev L, Baraliakos X, Conaghan PG, D'Agostino MA, Iagnocco A, van der Laken CJ, Ostergaard M, Naredo E.

RMD Open. 2019 Jun 25;5(2):e000950. doi: 10.1136/rmdopen-2019-000950. eCollection 2019.

31.

[Rheumatological care in the Rheumazentrum Ruhrgebiet Rheumatism Center-a model for conurbations].

Braun J, Kiltz U, Andreica I, Buehring B, Guminski B, Häusler U, Kavruk H, Kiefer D, Lochowski R, Mintrop B, Baraliakos X.

Z Rheumatol. 2019 Oct;78(8):753-764. doi: 10.1007/s00393-019-0663-2. Review. German.

PMID:
31286192
32.

Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis.

Mease P, Walsh JA, Baraliakos X, Inman R, de Vlam K, Wei JC, Hunter T, Gallo G, Sandoval D, Zhao F, Dong Y, Bolce R, Marzo-Ortega H.

Rheumatol Ther. 2019 Sep;6(3):435-450. doi: 10.1007/s40744-019-0165-3. Epub 2019 Jun 28.

33.

EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases.

Gossec L, Kedra J, Servy H, Pandit A, Stones S, Berenbaum F, Finckh A, Baraliakos X, Stamm TA, Gomez-Cabrero D, Pristipino C, Choquet R, Burmester GR, Radstake TRDJ.

Ann Rheum Dis. 2020 Jan;79(1):69-76. doi: 10.1136/annrheumdis-2019-215694. Epub 2019 Jun 22.

PMID:
31229952
34.

Imaging in axial spondyloarthritis: Changing concepts and thresholds.

Weber U, Baraliakos X.

Best Pract Res Clin Rheumatol. 2018 Jun;32(3):342-356. doi: 10.1016/j.berh.2018.10.009. Epub 2018 Nov 17. Review.

PMID:
31171307
35.

[Multi-Faceted Symptoms with Joint Pain, Exanthema and Eye Involvement].

Tsiami S, Regel A, Baraliakos X, Braun J, Kiltz U.

Dtsch Med Wochenschr. 2019 Jun;144(11):759-763. doi: 10.1055/a-0859-3151. Epub 2019 Jun 4. German.

PMID:
31163477
36.

What constitutes the fat signal detected by MRI in the spine of patients with ankylosing spondylitis? A prospective study based on biopsies obtained during planned spinal osteotomy to correct hyperkyphosis or spinal stenosis.

Baraliakos X, Boehm H, Bahrami R, Samir A, Schett G, Luber M, Ramming A, Braun J.

Ann Rheum Dis. 2019 Sep;78(9):1220-1225. doi: 10.1136/annrheumdis-2018-214983. Epub 2019 May 23.

PMID:
31122911
37.

Structural progression in axial spondyloarthritis.

Aouad K, Ziade N, Baraliakos X.

Joint Bone Spine. 2020 Mar;87(2):131-136. doi: 10.1016/j.jbspin.2019.04.006. Epub 2019 May 5.

PMID:
31067506
38.

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.

Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, Leonardi C, Porter B, Das Gupta A, Widmer A, Pricop L, Fox T.

Arthritis Res Ther. 2019 May 2;21(1):111. doi: 10.1186/s13075-019-1882-2.

39.

Added Value of Anti-CD74 Autoantibodies in Axial SpondyloArthritis in a Population With Low HLA-B27 Prevalence.

Ziade NR, Mallak I, Merheb G, Ghorra P, Baerlecken N, Witte T, Baraliakos X.

Front Immunol. 2019 Mar 26;10:574. doi: 10.3389/fimmu.2019.00574. eCollection 2019.

40.

Surgical treatment of anterior cervical osteophytes causing dysphagia.

Ruetten S, Baraliakos X, Godolias G, Komp M.

J Orthop Surg (Hong Kong). 2019 May-Aug;27(2):2309499019837424. doi: 10.1177/2309499019837424.

PMID:
30909798
41.

Tapering bDMARDs in axial SpA - what is the current evidence?

Ziade NR, Baraliakos X.

Nat Rev Rheumatol. 2019 Jun;15(6):322-324. doi: 10.1038/s41584-019-0201-2. No abstract available.

PMID:
30903025
42.

Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study Subanalysis.

Braun J, Baraliakos X, Kiltz U, Krüger K, Burmester GR, Wassenberg S, Thomas MH.

J Rheumatol. 2020 Jan;47(1):35-41. doi: 10.3899/jrheum.181040. Epub 2019 Mar 15.

43.

[RABBIT-SpA: a new disease register for axial spondyloarthritis and psoriatic arthritis].

Regierer AC, Weiß A, Baraliakos X, Zink A, Listing J, Strangfeld A.

Z Rheumatol. 2020 Mar;79(2):135-142. doi: 10.1007/s00393-019-0613-z. German.

PMID:
30874933
44.

Detection of Erosions in Sacroiliac Joints of Patients with Axial Spondyloarthritis Using the Magnetic Resonance Imaging Volumetric Interpolated Breath-hold Examination.

Baraliakos X, Hoffmann F, Deng X, Wang YY, Huang F, Braun J.

J Rheumatol. 2019 Nov;46(11):1445-1449. doi: 10.3899/jrheum.181304. Epub 2019 Feb 15.

PMID:
30770520
45.

HLA-B27 prevalence in axial spondyloarthritis patients and in blood donors in a Lebanese population: Results from a nationwide study.

Ziade N, Abi Karam G, Merheb G, Mallak I, Irani L, Alam E, Messaykeh J, Menassa J, Mroue' K, Uthman I, Masri AF, Ghorra P, Witte T, Baraliakos X.

Int J Rheum Dis. 2019 Apr;22(4):708-714. doi: 10.1111/1756-185X.13487. Epub 2019 Feb 6.

PMID:
30729696
46.

The need for comparative data in spondyloarthritis.

Choy E, Baraliakos X, Behrens F, D'Angelo S, de Vlam K, Kirkham BW, Østergaard M, Schett GA, Rissler M, Chaouche-Teyara K, Perella C.

Arthritis Res Ther. 2019 Jan 22;21(1):32. doi: 10.1186/s13075-019-1812-3.

47.

Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study.

Braun J, Baraliakos X, Deodhar A, Poddubnyy D, Emery P, Delicha EM, Talloczy Z, Porter B.

Rheumatology (Oxford). 2019 May 1;58(5):859-868. doi: 10.1093/rheumatology/key375.

48.

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies.

Braun J, Deodhar A, Landewé R, Baraliakos X, Miceli-Richard C, Sieper J, Quebe-Fehling E, Martin R, Porter B, Gandhi KK, van der Heijde D; MEASURE 1 and MEASURE 2 study groups.

RMD Open. 2018 Nov 21;4(2):e000749. doi: 10.1136/rmdopen-2018-000749. eCollection 2018.

49.

Active and chronic sacroiliitis, spondylitis and enthesitis, How specific are imaging findings for axial spondyloarthritis?

Braun J, Baraliakos X.

Rheumatology (Oxford). 2019 Aug 1;58(8):1321-1324. doi: 10.1093/rheumatology/key372. No abstract available.

PMID:
30561682
50.

The role of C-reactive protein as a predictor of treatment response in patients with ankylosing spondylitis.

Baraliakos X, Szumski A, Koenig AS, Jones H.

Semin Arthritis Rheum. 2019 Jun;48(6):997-1004. doi: 10.1016/j.semarthrit.2018.10.019. Epub 2018 Nov 2.

PMID:
30473179

Supplemental Content

Loading ...
Support Center